Showing that an experimental Alzheimer’s therapy delivers meaningful cognitive change is hard enough. But increasingly, AD drug sponsors face an additional challenge: making sure the tests capturing ...
Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild AD Improvement in cognition measured by ADAS-Cog 11 at three months is ...
Confirming once again that not only anti-amyloid therapeutic approaches struggle to score a win in Alzheimer’s and related dementias, the 10th CTAD conference, held November 1–4 in Boston, featured ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results